Cardiol Therapeutics (CRDL) Cash from Financing Activities (2020 - 2026)

Cardiol Therapeutics (CRDL) has 7 years of Cash from Financing Activities data on file, last reported at $9.9 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 102887.35% year-over-year to $9.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.1 million (up 56.96% YoY) and the FY2025 annual result came in at $11.1 million, down 17.38% from the prior year.
• Cash from Financing Activities eased to $9.9 million in Q1 2026, from $11.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $13.4 million in Q4 2024 to a low of -$10614.8 in Q3 2022.
• A 5-year average of $2.0 million and a median of -$10059.5 in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 131673.49% — and 2025, when it tumbled 197.35%.
• Tracing CRDL's Cash from Financing Activities over 5 years: stood at -$10198.9 in 2022, then climbed by 0.29% to -$10168.9 in 2023, then surged by 131673.49% to $13.4 million in 2024, then retreated by 16.67% to $11.1 million in 2025, then declined by 11.05% to $9.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $9.9 million (Q1 2026), $11.1 million (Q4 2025), and -$10059.5 (Q3 2025), per Business Quant data.